Here's why Eli Lilly bounced back, plus mega-caps lag while staples stocks rise

• Cramer says 'so many things are working' in the market. Here are a few bright spots

  Business - CNBC - November 8

• Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?

  Business - MarketWatch - October 30

• Eli Lilly's quarter was messy. What to do with the stock is more clear-cut

  Business - CNBC - October 30

• Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed

  Business - CNBC - October 30

• Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance

  Business - CNBC - October 30

More from CNBC

• Target's recent trade imports data tells the real story behind massive earnings miss

  Business - CNBC - 9 minutes ago

• Bitcoin hits fresh record, races toward $100,000 as rally continues

  Business - CNBC - 8 minutes ago

• Trump and Fed Chair Powell could be set on a collision course over interest rates

  Business - CNBC - 1 hour ago

• Nvidia says it will sell more of its next-generation Blackwell chips than previously anticipated

  Business - CNBC - 13 hours ago

• CFPB expands oversight of digital payments services including Apple Pay, Cash App, PayPal and Zelle

  Business - CNBC - 1 minute ago